N-[3-[1-cyclopropyl-1-(2,4-difluorophenyl)ethyl]-1H-indol-7-yl]methanesulfonamide | 737802-76-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-[1-cyclopropyl-1-(2,4-difluorophenyl)ethyl]-1H-indol-7-yl]methanesulfonamide
• CAS: 737802-76-5
• 化学式: C₂₀H₂₀F₂N₂O₂S
• 分子量: 390.454
• InChiKey: NOUXCOKPRXVTDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  70.3
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS<br/>[FR] MODULATEURS A BASE DE DERIVES INDOLIQUES DES RECEPTEURS NUCLEAIRES DES HORMONES STEROIDES
  申请人：LILLY CO ELI

  公开号：WO2004067529A1

  公开（公告）日：2004-08-12

  The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

  本发明提供了一种I式化合物或其药学上可接受的盐，包括I式化合物的有效量与适当载体、稀释剂或赋形剂组合而成的药物组合物，以及治疗生理紊乱的方法，特别是充血性心脏病，包括向患者施用I式化合物的有效量。
• THE USE OF NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES
  申请人：Bayer Aktiengesellschaft

  公开号：EP3566704A1

  公开（公告）日：2019-11-13

  The present disclosure relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to MRAs alone (preferably finerenone), or preferably in combination with sGC stimulators and/or sGC activators (preferably BAY 41-2272), for use in the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).

  本公开涉及非甾体类矿物皮质激素受体（MR）和矿物皮质激素受体拮抗剂（MR 拮抗剂，MRAs）的药理学。特别是，本发明涉及单独使用（优选非格列酮）或优选与sGC刺激剂和/或sGC激活剂（优选BAY 41-2272）联合使用的MRAs，用于预防和/或治疗肌肉或神经肌肉疾病，特别是治疗杜氏肌肉萎缩症（DMD）。
• Combination containing SGC stimulators and mineralocorticoid receptor antagonists
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10918639B2

  公开（公告）日：2021-02-16

  The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

  本发明涉及可溶性鸟苷酸环化酶刺激剂（sGC 刺激剂）与矿质皮质激素受体拮抗剂（MR 拮抗剂）的组合，以及该组合在治疗和/或预防心脏和心血管疾病、肾脏和心肾疾病、肺部和心肺疾病以及治疗和/或预防纤维化疾病方面的用途。
• Combination containing sGC activators and mineralocorticoid receptor antagonists
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US11331308B2

  公开（公告）日：2022-05-17

  The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

  本发明涉及可溶性鸟苷酸环化酶激活剂（sGC 激活剂）与矿质皮质激素受体拮抗剂（MR 拮抗剂）的组合，以及该组合在治疗和/或预防心脏和心血管疾病、肾脏和心肾疾病、肺部和心肺疾病以及治疗和/或预防纤维化疾病方面的用途。
• COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20190224176A1

  公开（公告）日：2019-07-25

  The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.